Literature DB >> 19695244

F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.

Liesbeth A Bruins Slot1, Fabrice Lestienne, Catherine Grevoz-Barret, Adrian Newman-Tancredi, Didier Cussac.   

Abstract

Brain region-specific modulation of immediate-early gene (IEG) may constitute a marker of antipsychotic drug-like activity. We investigated the effects of the putative antipsychotic drug N-[(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)ethyl]-3-(cyclopent-1-enyl)-benzylamine (F15063), a compound that targets both dopamine D(2) and serotonin 5-HT(1A) receptors, in comparison with haloperidol and clozapine on rat mRNA expression of IEG i.e. the zinc-fingered transcription factors c-fos, fosB, zif268, c-jun and junB, two transcription factors of the nuclear receptor family nur77 and nor1, and the effector IEG arc. F15063 (10 mg/kg) and clozapine (10 mg/kg), but not haloperidol (0.63 mg/kg), induced c-fos and fosB mRNA expression in prefrontal cortex, a region associated with control of cognition and negative symptoms of schizophrenia. In striatum, only c-fos, fosB, junB and nur77 were induced by clozapine whereas all IEG mRNAs were increased by haloperidol and F15063 (from 2.5 mg/kg) with similar high efficacy despite a total absence of F15063-induced catalepsy. However, at 0.63 mg/kg, F15063 induced a lower degree of striatal IEG mRNA expression than haloperidol and pretreatment with the serotonin 5-HT(1A) receptor antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl-N-(2-pyridinyl)cyclohexane carboxamide trihydrochloride (WAY100635) (0.63 mg/kg) increased the level of IEG mRNA induction by F15063. Furthermore, (+)-8-hydroxy-2-(di-n-propylamino)tetralin [(+)-8-OH-DPAT] at 0.16 mg/kg decreased haloperidol-induced striatal IEG mRNA expression although it exerted no effects on its own. These results are consistent with an activation of serotonin 5-HT(1A) receptors by F15063, thus reducing D(2) blockade-induced striatal IEG mRNA. Furthermore, the substantial F15063-induced expression of IEGs such as c-fos in striatum is not related to cataleptogenic activity and may act more as a marker of efficacious dopamine D(2) receptor blockade.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19695244     DOI: 10.1016/j.ejphar.2009.08.019

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

1.  The effects of clozapine on quinpirole-induced non-regulatory drinking and prepulse inhibition disruption in rats.

Authors:  Lorenza De Carolis; Maria Antonietta Stasi; Ottaviano Serlupi-Crescenzi; Franco Borsini; Paolo Nencini
Journal:  Psychopharmacology (Berl)       Date:  2010-07-10       Impact factor: 4.530

Review 2.  The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment.

Authors:  Herbert Y Meltzer; Masakuni Horiguchi; Bill W Massey
Journal:  Psychopharmacology (Berl)       Date:  2011-01-08       Impact factor: 4.530

3.  Modulation of haloperidol-induced patterns of the transcription factor Nur77 and Nor-1 expression by serotonergic and adrenergic drugs in the mouse brain.

Authors:  Jérôme Maheux; Laura Vuillier; Mylène Mahfouz; Claude Rouillard; Daniel Lévesque
Journal:  Int J Neuropsychopharmacol       Date:  2011-04-28       Impact factor: 5.176

4.  The dopaminergic stabilizers pridopidine and ordopidine enhance cortico-striatal Arc gene expression.

Authors:  Susanna Waters; Henrik Ponten; Malin Edling; Boel Svanberg; Daniel Klamer; Nicholas Waters
Journal:  J Neural Transm (Vienna)       Date:  2014-05-11       Impact factor: 3.575

5.  Brain edema and protein expression of c-Fos and c-Jun in the brain after diffused brain injury.

Authors:  Wei Zheng; Lijian Niu; Chunpu Zhang; Chao Zhu; Fangmin Xie; Chunguang Cao; Gang Li
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

6.  Altered gene expression in schizophrenia: findings from transcriptional signatures in fibroblasts and blood.

Authors:  Nadia Cattane; Alessandra Minelli; Elena Milanesi; Carlo Maj; Stefano Bignotti; Marco Bortolomasi; Luisella Bocchio Chiavetto; Massimo Gennarelli
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

7.  Post-mortem molecular profiling of three psychiatric disorders.

Authors:  Ryne C Ramaker; Kevin M Bowling; Brittany N Lasseigne; Megan H Hagenauer; Andrew A Hardigan; Nicholas S Davis; Jason Gertz; Preston M Cartagena; David M Walsh; Marquis P Vawter; Edward G Jones; Alan F Schatzberg; Jack D Barchas; Stanley J Watson; Blynn G Bunney; Huda Akil; William E Bunney; Jun Z Li; Sara J Cooper; Richard M Myers
Journal:  Genome Med       Date:  2017-07-28       Impact factor: 11.117

Review 8.  The Role of Early Growth Response 1 (EGR1) in Brain Plasticity and Neuropsychiatric Disorders.

Authors:  Florian Duclot; Mohamed Kabbaj
Journal:  Front Behav Neurosci       Date:  2017-03-06       Impact factor: 3.558

Review 9.  A critical evaluation of the activity-regulated cytoskeleton-associated protein (Arc/Arg3.1)'s putative role in regulating dendritic plasticity, cognitive processes, and mood in animal models of depression.

Authors:  Yan Li; Alan L Pehrson; Jessica A Waller; Elena Dale; Connie Sanchez; Maria Gulinello
Journal:  Front Neurosci       Date:  2015-08-10       Impact factor: 4.677

Review 10.  Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease.

Authors:  Susanna Waters; Joakim Tedroff; Henrik Ponten; Daniel Klamer; Clas Sonesson; Nicholas Waters
Journal:  J Huntingtons Dis       Date:  2018
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.